S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
On Friday, UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% upside from the current price of $13.03. Alvotech, a company specializing in biosimilars with a business-to-business sales approach and a market capitalization of $3.85 billion, is considered to have cautious market sentiment due to its historical performance and unclear visibility into Humira prescriptions. Despite this, UBS forecasts Alvotech's sales to reach $1.6 billion by 2028, which contrasts with the $1.2 billion currently factored into the stock price.
UBS's stance is that consistent strong sales over the upcoming three to four quarters could lead to a reassessment of the company's market value, potentially aligning it with UBS's higher sales projections. The firm suggests that forthcoming updates on biosimilar Humira (b-Humira) could provide positive news in the near term. Additionally, the potential of biosimilar Stelara (b-Stelara) is highlighted as a source of further upside in the second half of 2025. According to InvestingPro, the stock has shown low price volatility and tends to move counter to market trends with a beta of -0.19, potentially offering portfolio diversification benefits.
The analysis also points to the possibility of Alvotech's stock outperforming as a result of a growing product pipeline and the achievement of development and performance milestones. While the company maintains a healthy liquidity position with a current ratio of 2.69, InvestingPro subscribers can access 5 additional ProTips and comprehensive analysis through the Pro Research Report. UBS's commentary indicates a belief in the company's potential to exceed current market expectations through sustained sales growth and strategic development in its pipeline.
In other recent news, Alvotech has reported substantial growth in its revenues, reaching $128 million for the first nine months of 2024. This figure is nearly nine times the revenue reported for the same period in 2023. One of the significant contributors to this growth was the successful introduction of biosimilars and increased manufacturing utilization, which significantly improved the company's gross margins.
Milestone (WA:MMD) revenues have surpassed $210 million. Alvotech's robust pipeline, including biosimilar candidates AVT16, AVT03, and AVT05, continues to progress, contributing to these impressive figures. Regulatory milestones have been achieved, and commercial strategies are ramping up supply in various markets.
The U.S. FDA GMP inspection of Alvotech's Reykjavik site was completed successfully, albeit with two observations noted. The company is also expanding its biosimilar Humira supply in the U.S. and launching biosimilars in multiple international markets.
In terms of future plans, Alvotech aims to launch its Eylea biosimilar in Europe in 2025. Applications for biosimilars of Simponi and Prolia/Xgeva have been accepted by the EMA, with U.S. submissions expected by the end of the year. Despite the uncertainties in product shipments moving into 2025, Alvotech remains confident in maintaining a revenue guidance of $400 million to $500 million for 2024 and $600 million to $800 million for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.